

The ocular safety of hydroxychloroquine

Seminars in Arthritis and Rheumatism

23, 62-67

DOI: [10.1016/s0049-0172\(10\)80009-5](https://doi.org/10.1016/s0049-0172(10)80009-5)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Distribution of the enantiomers of hydroxychloroquine and its metabolites in ocular tissues of the rabbit after oral administration of racemic-hydroxychloroquine. <i>Chirality</i> , 1994, 6, 347-354.	1.3	22
2	Using chirality as a unique probe of pharmacological properties. <i>Journal of Chromatography A</i> , 1995, 694, 169-179.	1.8	15
3	Adverse Effects of Chemotherapeutic Agents Used in Tropical Medicine. <i>Drug Safety</i> , 1995, 13, 31-45.	1.4	10
4	The Use of Slower-Acting (Class III) Symptom-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. <i>BioDrugs</i> , 1996, 5, 309-325.	0.7	1
5	Guidelines for monitoring drug therapy in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1996, 39, 723-731.	6.7	227
6	New considerations in monitoring for hydroxychloroquine retinopathy. <i>Clinical Eye and Vision Care</i> , 1996, 8, 99-104.	0.1	3
7	Retinal toxicity in long term hydroxychloroquine treatment.. <i>Annals of the Rheumatic Diseases</i> , 1996, 55, 187-189.	0.5	94
8	Sarcoidosis. <i>New England Journal of Medicine</i> , 1997, 337, 789-791.	13.9	0
9	Recognition and Management of Systemic Lupus Erythematosus. <i>Drugs</i> , 1997, 54, 422-434.	4.9	17
10	Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. <i>Arthritis and Rheumatism</i> , 1997, 40, 1482-1486.	6.7	233
11	Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 102, 198-203.	1.5	30
12	Hydroxychloroquine: past, present, future. <i>Lupus</i> , 1998, 7, 65-67.	0.8	34
13	Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: A randomized, double-blind six-week trial with eighteen-week extension. <i>Arthritis and Rheumatism</i> , 1999, 42, 357-365.	6.7	78
14	Management of patients undergoing hydroxychloroquine (Plaquenil) therapy. <i>Australasian journal of optometry</i> , The, 2000, 83, 32-36.	0.6	9
15	ANTIMALARIALS. <i>Dermatologic Clinics</i> , 2001, 19, 147-160.	1.0	67
16	Antimalarials. <i>Dermatologic Therapy</i> , 2001, 14, 143-153.	0.8	1
17	Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity11InternetAdvance publication at ajo.com April 24, 2002.. <i>American Journal of Ophthalmology</i> , 2002, 133, 649-656.	1.7	105
18	Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 1460-1469.	6.7	219

#	ARTICLE	IF	CITATIONS
19	Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. <i>Apmis</i> , 2002, 110, 481-489.	0.9	116
20	The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine. <i>Ophthalmology</i> , 2003, 110, 1321-1326.	2.5	236
21	Detecting chloroquine retinopathy: electro-oculogram versus colour vision. <i>British Journal of Ophthalmology</i> , 2003, 87, 902-908.	2.1	46
22	The Multifocal Pattern Electroretinogram in Chloroquine Retinopathy. <i>Ophthalmic Research</i> , 2004, 36, 106-113.	1.0	13
23	Threshold Amsler grid as a screening tool for asymptomatic patients on hydroxychloroquine therapy. <i>British Journal of Ophthalmology</i> , 2005, 89, 569-574.	2.1	22
24	Combination Antimalarials in the Treatment of Cutaneous Dermatomyositis. <i>Archives of Dermatology</i> , 2005, 141, 855-9.	1.7	78
25	Management of Cutaneous Dermatomyositis. <i>American Journal of Clinical Dermatology</i> , 2006, 7, 341-351.	3.3	41
26	Hydroxychloroquine in the treatment of chronic erythema nodosum. <i>British Journal of Dermatology</i> , 1995, 132, 661-662.	1.4	23
27	New concepts in antimalarial use and mode of action in dermatology. <i>Dermatologic Therapy</i> , 2007, 20, 160-174.	0.8	234
28	Ocular Toxicity of Hydroxychloroquine. <i>Seminars in Ophthalmology</i> , 2008, 23, 201-209.	0.8	91
30	Detection of the regression on hydroxychloroquine retinopathy in optical coherence tomography. <i>Clinical Rheumatology</i> , 2009, 28, 607-609.	1.0	17
31	A comparative study of the usefulness of color vision, photostress recovery time, and visual evoked potential tests in early detection of ocular toxicity from hydroxychloroquine. <i>International Ophthalmology</i> , 2011, 31, 283-289.	0.6	17
33	Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: A pilot study. <i>Journal of Dermatology</i> , 2012, 39, 531-535.	0.6	23
34	Antimalarial Medications. , 2013, , 601-608.		3
35	Re: Monitoring patients on antimalarials: where are we now?. <i>Canadian Journal of Ophthalmology</i> , 2013, 48, 218.	0.4	3
36	Impact of the Revised American Academy of Ophthalmology Guidelines Regarding Hydroxychloroquine Screening on Actual Practice. <i>American Journal of Ophthalmology</i> , 2013, 155, 418-428.e1.	1.7	61
37	Relative sensitivity and specificity of 10-2 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy. <i>Clinical Ophthalmology</i> , 2014, 8, 1389.	0.9	49
38	Chloroquine and hydroxychloroquine binding to melanin: Some possible consequences for pathologies. <i>Toxicology Reports</i> , 2014, 1, 963-968.	1.6	56

#	ARTICLE	IF	CITATIONS
39	Hydroxychloroquine and Chloroquine Retinopathy. , 2014, , .		47
40	Pharmacology of Chloroquine and Hydroxychloroquine. , 2014, , 35-63.		94
41	Chloroquine and Hydroxychloroquine Increase Retinal Pigment Epithelial Layer Permeability. Journal of Biochemical and Molecular Toxicology, 2015, 29, 299-304.	1.4	28
42	Hydroxychloroquine Retinopathy. Journal of Rheumatic Diseases, 2015, 22, 140.	0.4	0
43	Detection of Hydroxychloroquine Retinal Toxicity by Automated Perimetry in 60 Rheumatoid Arthritis Patients with Normal Fundoscopic Findings. Global Journal of Health Science, 2015, 8, 59.	0.1	7
44	Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease. Canadian Journal of Ophthalmology, 2015, 50, 442-450.	0.4	26
45	A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye. Clinical Reviews in Allergy and Immunology, 2015, 49, 317-326.	2.9	91
46	Hydroxychloroquine Screening Practice Patterns Within a Large Multispecialty Ophthalmic Practice. American Journal of Ophthalmology, 2015, 160, 561-568.e2.	1.7	19
47	Evaluation of a follow-up protocol for patients on chloroquine and hydroxychloroquine treatment. Archivos De La Sociedad Espanola De Oftalmologia, 2016, 91, 10-14.	0.1	2
48	Evaluaci3n de un protocolo de seguimiento de pacientes en tratamiento con antipal4dicos. Archivos De La Sociedad Espanola De Oftalmologia, 2016, 91, 10-14.	0.1	4
49	Corneal thickness and endothelial changes in long-term hydroxychloroquine use. Cutaneous and Ocular Toxicology, 2019, 38, 286-289.	0.5	5
50	Antimalarial Medications. , 2019, , 650-660.		0
51	Natural history of COVID-19 and current knowledge on treatment therapeutic options. Biomedicine and Pharmacotherapy, 2020, 129, 110493.	2.5	118
52	Current pharmacological treatments for COVID19: What's next?. British Journal of Pharmacology, 2020, 177, 4813-4824.	2.7	210
53	Evaluation of corneal safety in systemic lupus erythematosus patients undergoing long-term hydroxychloroquine treatment. Cutaneous and Ocular Toxicology, 2021, 40, 21-25.	0.5	2
54	Toxicology of Hydroxychloroquine and Chloroquine and the Pathology of the Retinopathy They Cause. , 2014, , 65-83.		3
57	Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. BJGP Open, 2020, 4, bjgpopen20X101069.	0.9	86
58	Ocular side effects of systemic drugs used in dermatology. Indian Journal of Dermatology, 2019, 64, 423.	0.1	2

#	ARTICLE	IF	CITATIONS
59	Clinical, pharmacokinetic and technological aspects of the hydroxychloroquine sulfate. IOSR Journal of Pharmacy, 2014, 04, 53-64.	0.1	1
60	Chronic joint pain. , 2008, , 518-536.		0
61	Ancillary Testing in Screening for Hydroxychloroquine and Chloroquine Retinopathy. , 2014, , 155-226.		0
62	Screening for Hydroxychloroquine and Chloroquine Retinopathy. , 2014, , 227-245.		0
63	Risk Factors for Hydroxychloroquine and Chloroquine Retinopathy. , 2014, , 133-154.		0
64	Definitions of Hydroxychloroquine and Chloroquine Retinopathy. , 2014, , 85-94.		0
65	Natural History of Hydroxychloroquine and Chloroquine Retinopathy. , 2014, , 107-131.		0
66	GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition. Viruses, 2022, 14, 132.	1.5	10